Program
Verteporfin
Also written as “Verteporfin Photodynamic Therapy”, “Verteporfin Injection” and “Photodynamic Therapy (PDT) with Visudyne (verteporfin)”.
Its studies are mostly in Macular Degeneration · Prostatic Neoplasms · Breast Neoplasms · Polypoidal Choroidal Vasculopathy, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 40 open or running | phase 4since Aug 24, 2005 | Aug 24, 2005 | none ahead |
| SpectraCure AB | 22 open or running | phase 2since Feb 13, 2017 | Feb 13, 2017 | Jul 31, 2027phase 2 · NCT03067051 |
| QLT | 10 open or running | phase 3since Jul 12, 2005 | Jul 12, 2005 | none ahead |
| Rogers Sciences | 10 open or running | phase 2since Oct 18, 2016 | Oct 18, 2016 | none ahead |
Also a collaborator on its studies: Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2005First study: phase 3 study in Macular DegenerationNew to QLTQLT · NCT00121407 · 364 enrolled
- Aug 24, 2005Novartis's first study: phase 4 study in Macular DegenerationNew to NovartisNovartis · NCT00135837 · 202 enrolled · Switzerland
- Feb 8, 20072 phase 3 studies in Macular DegenerationNovartis · NCT00433017, NCT00436553
- May 5, 2008Phase 4 study in Polypoidal Choroidal VasculopathyNovartis · NCT00674323 · 61 enrolled · Hong Kong, Korea, Republic of, Singapore and more
- Oct 18, 2016Rogers Sciences's first study: phase 2 study in Breast NeoplasmsNew to Rogers SciencesRogers Sciences · NCT02939274 · 15 enrolled · United States
- Feb 13, 2017SpectraCure AB's first study: phase 2 study in Prostatic NeoplasmsNew to SpectraCure ABSpectraCure AB · NCT03067051 · 66 planned · United States, Canada, Sweden and more
- Jan 29, 2025Phase 2 study in Prostatic NeoplasmsSpectraCure AB · NCT06807359 · 43 planned · United States, Germany
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Prostatic NeoplasmsSpectraCure AB · NCT03067051
- Jan 2028Primary completion: phase 2 study in Prostatic NeoplasmsSpectraCure AB · NCT06807359
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06807359Prostatic Neoplasms · United States, Germany | 2 | Recruiting | SpectraCure AB | Jan 2028 | 43 |
| NCT03067051Prostatic Neoplasms · United States, Canada, Sweden and more | 2 | Recruiting | SpectraCure AB | Jul 31, 2027 | 66 |
| NCT02939274Breast Neoplasms · United States | 2 | UNKNOWN | Rogers Sciences | Dec 2018 | 15 |
| NCT00674323Polypoidal Choroidal Vasculopathy · Hong Kong, Korea, Republic of, Singapore and more | 4 | Completed | Novartis | May 2009 | 61 |
| NCT00436553Macular Degeneration · United States, Canada | 3 | Completed | Novartis | Oct 2009 | 321 |
| NCT00433017Macular Degeneration · Austria, Belgium, Denmark and more | 3 | Terminated | Novartis | Jul 2009 | 255 |
| NCT00135837Macular Degeneration · Switzerland | 4 | Completed | Novartis | 202 | |
| NCT00121407Macular Degeneration | 3 | Completed | QLT | 364 |
How it is read
Names in the registry
- “Verteporfin Photodynamic Therapy”, 3 entries
- “Verteporfin”, 2 entries
- “Verteporfin Injection”, 1 entry
- “Photodynamic Therapy (PDT) with Visudyne (verteporfin)”, 1 entry
- “Verteporfin for injection”, 1 entry
Conditions, from the studies’ own filings
- Macular Degeneration, 5 studies
- Prostatic Neoplasms, 2 studies
- Breast Neoplasms, 1 study
- Polypoidal Choroidal Vasculopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.